ivermectin + doxycycline + zinc

**Ivermectin + doxycycline + zinc** is a combination therapy comprising the antiparasitic agent ivermectin, the tetracycline antibiotic doxycycline, and the essential mineral zinc, primarily used to treat bacterial and parasitic infections such as scabies and intestinal worms. Ivermectin paralyzes and kills parasites by binding to glutamate-gated chloride channels, doxycycline inhibits bacterial protein synthesis via the 30S ribosomal subunit, and zinc supports immune function and may enhance antiviral effects as a cofactor. This multidrug regimen has been explored off-label for COVID-19 treatment and prophylaxis, leveraging doxycycline's zinc ionophore properties to increase intracellular zinc levels that inhibit viral replication, alongside ivermectin's potential antiviral activity against RNA viruses including SARS-CoV-2; it is administered orally, often in 10-day courses, but lacks formal regulatory approval for viral indications and requires medical supervision due to potential interactions and side effects like nausea, diarrhea, and dizziness.[1][3][5]

Brand names

Ziverdox-TZiverdox-P

Other names

zinc acetate + doxycycline + ivermectin